Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGPhase 2INTERVENTIONAL

A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus

A Randomized, Double-blind, Placebo-controlled Study Investigating the Effect of ALN-4324 on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM

Who May Be Eligible (Plain English)

Who May Qualify: - Is an adult patient with a confirmed diagnosis of T2DM - Has a body mass index (BMI) of ≥25 kg/m\^2 and \<39.9 kg/m\^2 - Has a hemoglobin A1c (HbA1c) ≥6.5% to \<10.5% - Is on a stable dose of metformin Who Should NOT Join This Trial: - Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results - Receiving therapies known to interfere with glucose or insulin metabolism other than current treatment for T2DM or birth control methods Note: other protocol defined inclusion/exclusion criteria apply Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Is an adult patient with a confirmed diagnosis of T2DM * Has a body mass index (BMI) of ≥25 kg/m\^2 and \<39.9 kg/m\^2 * Has a hemoglobin A1c (HbA1c) ≥6.5% to \<10.5% * Is on a stable dose of metformin Exclusion Criteria: * Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results * Receiving therapies known to interfere with glucose or insulin metabolism other than current treatment for T2DM or birth control methods Note: other protocol defined inclusion/exclusion criteria apply

Treatments Being Tested

DRUG

ALN-4324

ALN-4324 will be administered subcutaneously (SC).

DRUG

Placebo

Placebo will be administered SC.

Locations (1)

Clinical Trial Site
Chula Vista, California, United States